Premium
Translating the MDS flow cytometric score into clinical practice
Author(s) -
Heron Michiel,
Dovern Elisabeth,
BakkerJonges Liesbeth E.,
Posthuma Eduardus F.M.,
Brouwer Rolf E.,
Smedts Frank,
Batstra Manou R.
Publication year - 2014
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21208
Subject(s) - myelodysplastic syndromes , cytopenia , myeloid , medicine , population , oncology , cd34 , dysplasia , stem cell , bone marrow , biology , genetics , environmental health
Myelodysplastic syndromes (MDS) are classified by the WHO as myeloid neoplasms, and are characterized by cytopenia and dysplasia in one or more myeloid cell lines. Recently, a flow cytometric score (FCM‐score) was published capable of discriminating low‐grade MDS from non‐clonal cytopenias (Della Porta et al., 2012). We tested the applicability of the FCM‐score in a patient population from a large peripheral teaching hospital in The Netherlands. The evaluation of the proposed FCM score in low‐grade MDS showed a high sensitivity and specificity, and clinically significant positive and negative likelihood ratios. The use of CD10 and CD19 positivity to identify progenitor B‐cell blasts provided a specific and precize method to separate progenitor B‐cell blasts from myeloid blasts within the CD34+/low CD45+ population and may be more convenient compared to the published method using low SSC and CD45 expression. This study confirms the value of utilizing the FCM‐score in our patient population. © 2014 International Clinical Cytometry Society © 2014 International Clinical Cytometry Society